Recursion Pharmaceuticals (RXRX)
(Delayed Data from NSDQ)
$7.02 USD
-0.32 (-4.36%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $7.01 -0.01 (-0.14%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Recursion Pharmaceuticals (RXRX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$11.57 | $17.00 | $8.00 | 57.63% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Recursion Pharmaceuticals comes to $11.57. The forecasts range from a low of $8.00 to a high of $17.00. The average price target represents an increase of 57.63% from the last closing price of $7.34.
Analyst Price Targets (7 )
Broker Rating
Recursion Pharmaceuticals currently has an average brokerage recommendation (ABR) of 2.63 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 2.57 a month ago based on seven recommendations.
Of the eight recommendations deriving the current ABR, one is Strong Buy and one is Buy. Strong Buy and Buy each account for 12.5% of all recommendations. A month ago, Strong Buy made up 14.29%, while Buy represented 14.29%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 6 | 6 | 5 | 5 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.63 | 2.63 | 2.57 | 2.57 | 2.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/11/2024 | KeyBanc Capital Markets | Scott Schoenhaus | Strong Buy | Strong Buy |
6/27/2024 | SVB Securities | Mani Foroohar | Hold | Hold |
4/9/2024 | Needham & Company | Gil J Blum | Moderate Buy | Moderate Buy |
4/1/2024 | Cowen & Co. | Steven Mah | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.63 |
ABR (Last week) | 2.63 |
# of Recs in ABR | 8 |
Average Target Price | $11.57 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 154 of 253 |
Current Quarter EPS Est: | -0.35 |